PATH | VRL
Menu

Find resources

Total results with these characteristics: 1851

Page 92 of 93
WHO Expert Consultation on Serotype Composition of Pneumococcal Conjugate Vaccines for Use in Resource-Poor Developing Countries, 26–27 October 2006, Geneva.

Published in the journal Vaccine, this article reports on a World Health Organization expert consultation to formulate a data-driven approach to determine the minimum or optimal formulation of pneumococcal conjugate vaccines, particularly keeping in …

Author: Cherian T

Publication date: 2007

WHO Global Action Plan to Minimize Poliovirus Facility-Associated Risk After Type-Specific Eradication of Wild Polioviruses and Sequential Cessation of Oral Polio Vaccine Use

This is the third edition of the Global Action Plan for eradicating polio. It includes suggested guidelines for the safe handling and containment of poliovirus infectious and potentially infectious materials, with the goal of reduced risk of …

Author: World Health Organization

Publication date: 2015

WHO Guidance Note: Vaccine Diluents, Revision 2015

This guidance note explains the proper handling and use of vaccine diluents, including critical steps for reconstituting vaccines safely and the appropriate storage and stock management procedures. This document is designed to be used in conjunction …

Author: World Health Organization

Publication date: 2015

WHO HPV Laboratory Network

The mission of the World Health Organization (WHO) global human papillomavirus (HPV) Laboratory Network (LabNet) is to contribute to improving quality of laboratory services for effective surveillance and monitoring of HPV vaccination impact, …

Author: World Health Organization

WHO Human Papillomavirus Vaccine Programmatic Resources

This web page provides links to further resources related to human papillomavirus vaccines. Topics include policy and decision making, implementation, and monitoring and surveillance.

Author: World Health Organization

WHO Initiative to Increase Global and Equitable Access to Influenza Vaccine in the Event of a Pandemic: Supporting Developing Country Production Capacity Through Technology Transfer

This article, published in Vaccine, showcases the interim results of the World Health Organization's technology transfer initiative to increase global and equitable access to influenza vaccine in the event of a pandemic. It highlights the progress …

Author: Friede M, Palkonyay L, Alfonso C, et al.

Publication date: 2011

WHO Policy Development Processes for a New Vaccine: Case Study of Malaria Vaccines

This article, published in Malaria Journal, analyzed the World Health Organization policy development process to predict its course for a malaria vaccine. Data needs for a malaria vaccine include safety; the demonstration of efficacy in a range of …

Author: Milstien J, Cardenas V, Cheyne J, Brooks A

Publication date: 2010

WHO Policy Statement: Multi-dose Vial Policy (MDVP) - Handling of Multi-dose Vaccine Vials After Opening

This document is designed to provide guidance to national and senior-level program managers on the proper handling of multi-dose vaccine vials once opened. It presents the World Health Organization’s official position on this issue, including the …

Author: World Health Organization

Publication date: 2014

WHO Preferred Product Characteristics for Group B Streptococcus Vaccines

This report provides guidance on vaccine development strategies and targets for group B Streptococcus vaccines. It includes key clinical research and development considerations as well as preferred product characteristics such as indication, target …

Author: World Health Organization

Publication date: 2017

WHO Preferred Product Characteristics for Respiratory Syncytial Virus (RSV) Vaccines

This report provides guidance on vaccine development strategies and targets for RSV vaccines. It includes key clinical research and development considerations as well as preferred product characteristics such as indication, target population, …

Author: World Health Organization

Publication date: 2017

WHO Preferred Product Characteristics (PPC) for Malaria Vaccines

This document provides guidance for vaccine manufacturers and funding agencies in refining their product development plans for malaria vaccines. It clarifies the World Health Organization's preferences with regard to many criteria that form part of …

Author: World Health Organization

Publication date: 2014

WHO Prequalified Vaccines

This web page provides a database of vaccines prequalified by the World Health Organization which allows the user to search by manufacturer, vaccine, or country of manufacture. The database is tailored to support immunization program managers, …

Author: World Health Organization

WHO Recommendations for Routine Immunization: Summary Tables

These summary tables are designed to assist program managers in developing optimal immunization schedules using key information from the World Health Organization (WHO). The first table summarizes recommended routine immunizations for all age …

Author: World Health Organization

Publication date: 2017

WHO Recommendations Regarding Vaccine Hesitancy

Vaccine hesitancy refers to delay in acceptance or refusal of safe vaccines despite availability of vaccination services. This special issue of Vaccine is guest-edited by the World Health Organization (WHO) and focuses on the topic of vaccine …

Author: Schuster M, Duclos P, eds.

Publication date: 2015

WHO Vaccine Reaction Rates Information Sheets

This web page provides links to information sheets on reaction rates of selected vaccines. The papers are primarily designed for use by national public health officials and immunization program managers. Data from these sheets can be used for the …

Author: World Health Organization

WHO/Health Canada Drafting Group Meeting on Scientific and Regulatory Considerations on the Stability Evaluation of Vaccines Under Controlled Temperature Chain

On December 4 to 6, 2012, a consultation was held under the auspices of the World Health Organization (WHO) and Health Canada in Ottawa to identify obstacles to further developing a controlled temperature chain for vaccines. As described in this …

Author: World Health Organization

Publication date: 2013

Whom and Where Are We Not Vaccinating? Coverage After the Introduction of a New Conjugate Vaccine Against Group A Meningococcus in Niger in 2010

The authors of this article, published in PLoS ONE, evaluated the first two phases of the introduction campaign of a new conjugate vaccine, MenAfriVac™, in Niger. They determined which sub-populations or areas …

Author: Kim SH, Pezzoli L, Yacouba H, et al.

Publication date: 2012

WHO's Key Normative Processes and Institutions for Vaccines: A Primer

This policy brief describes three World Health Organization (WHO) normative institutions and processes pertaining to the issuance of technical guidelines and opinons about the public health value of new vaccines, their quality, and the …

Author: International AIDS Vaccine Institute

Publication date: 2008

Why Invest in Communication for Immunization? Evidence and Lessons Learned

This report identifies communication challenges that affect the success of immunization services; offers evidence of the contributions of communication activities; identifies lessons learned, and suggests ways in which communication can continue to …

Author: Waisbord S and Larson H

Publication date: 2005

Will the Decade of Vaccines Mean Business as Usual?

The authors of this article, published in The Lancet, argue that anticipated advances in vaccinology during this new Decade of Vaccines (named by the Bill & Melinda Gates Foundation in January 2010) will only translate into reductions in …

Author: Rees H, Madhi SA

Publication date: 2011

Page 92 of 93